CN103948759A - Traditional Chinese medicine compound composition and application for treating fatty liver - Google Patents
Traditional Chinese medicine compound composition and application for treating fatty liver Download PDFInfo
- Publication number
- CN103948759A CN103948759A CN201410206652.0A CN201410206652A CN103948759A CN 103948759 A CN103948759 A CN 103948759A CN 201410206652 A CN201410206652 A CN 201410206652A CN 103948759 A CN103948759 A CN 103948759A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- traditional chinese
- compound composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine compound composition for treating fatty liver. The traditional Chinese medicine compound composition is prepared from the following raw materials in parts by weight: 10 to 30 parts of fructus citri, 20 to 40 parts of rheum officinale, 10 to 30 parts of rhizoma alismatis, 15 to 45 parts of salvia miltiorrhiza, 10 to 30 parts of polygonum multiflorum, 10 to 30 parts of szechwan chinaberry fruit, 20 to 30 parts of hippophae rhamnoides, 10 to 30 parts of radix puerariae, 10 to 30 parts of gynostemma pentaphylla, 10 to 20 parts of cowherb seed, 10 to 20 parts of pinellia ternate, 10 to 30 parts of lysimachia christinae hance, 20 to 40 parts of polygonum cuspidatum, 10 to 30 parts of radix paeoniae rubra, 10 to 30 parts of lucid ganoderma, and 10 to 20 parts of liquorice. The traditional Chinese medicine compound composition for treating fatty liver has the advantages that the formula is selected by the syndrome differentiation and treatment method in combination with pharmacological experiment according to the pathogenesis of fatty liver; all medicines in the formula are combined scientifically to realize the effects of reducing blood fat, lowering cholesterol, reducing both weight and fat, promoting blood circulation to remove blood stasis, soothing liver, promoting growth of liver cell, protecting liver, and improving liver function; therefore, the traditional Chinese medicine compound composition has a good effect on treating fatty liver; in addition, the traditional Chinese medicine compound composition is high in safety and has no toxic and side effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine, particularly relate to a kind of Traditional Chinese medicine compound composition with treatment fatty liver.
Background technology
Because the factors such as disease or medicine cause hepatocyte inner lipid, gather over 5% of liver weight in wet base, be referred to as fatty liver (fatty liver).The lipid of liver inner accumulated can be triacylglycerol, fatty acid, phospholipid or cholesteryl ester etc. according to cause of disease difference, wherein take triacylglycerol as many.According to fat content, fatty liver can be divided into light-duty (fatty 5%～10%), medium-sized (fatty 10%～25%), heavy (fatty 25%～50% or > 30%) three types.Fatty liver is a common clinical picture, rather than a disease independently, comprises the pathological changes such as steatosis, the sclerosis of fatty hepatitis regulating liver-QI.Clinically, according to onset emergency, fatty liver can be divided into acute and chronic two large classes.The former is relatively rare, shows as typical vesicle hepatocyte fat more and become on pathology; The latter mainly refers to that the bulla hepatocyte fat being caused by obesity, diabetes and excessive drinking etc. becomes.According to investigations, the Patients with Fatty Liver number because fat reason causes, raises year by year, so obesity controlling, and conditioning blood fat is to reduce the important means of prevention suffering from fatty liver.
At present more about the medicine of fatty liver, greatly mainly with being main by blood fat effect, but the medicine of prior art can, from fundamentally in effect for reducing fat, play well soothing the liver, hepatoprotective effect, so clinical efficacy be good.
Therefore, necessary on the technology of prior art, research and develop a kind of good blood fat reducing that has, soothing the liver, the Chinese medicine compound of hepatoprotective effect.
Summary of the invention
Goal of the invention: the object of the present invention is to provide a kind of have good effect for reducing blood fat, soothing the liver, invigorate blood circulation, improve liver function, safe, the Traditional Chinese medicine compound composition having no adverse reaction.
Technical scheme: in order to realize above object, the technical scheme that the present invention takes is:
A Traditional Chinese medicine compound composition with treatment fatty liver, it is made by the raw material of following parts by weight:
10～30 parts of Fructus Citris, 20～40 parts of Radix Et Rhizoma Rhei, 10～30 parts of Rhizoma Alismatis, 15～45 parts of Radix Salviae Miltiorrhizaes, 10～30 parts of Radix Polygoni Multiflori, 10～30 parts of Fructus Toosendans, 20～30 parts of Fructus Hippophaes, 10～30 parts of Radix Puerariaes, 10～30 parts of Herb Gynostemmae Pentaphylli, 10～20 parts of Semen Vaccariae, 10～20 parts of the Rhizoma Pinelliaes, 10～30 parts of Herba Lysimachiaes, 20～40 parts of Rhizoma Polygoni Cuspidati, 10～30 parts of Radix Paeoniae Rubra, 10～30 parts of Ganodermas, 10～20 parts, Radix Glycyrrhizae.
As preferred version, the above-described Traditional Chinese medicine compound composition with treatment fatty liver, it is made by the raw material of following parts by weight: 20～30 parts of Fructus Citris, 30～40 parts of Radix Et Rhizoma Rhei, 10～20 parts of Rhizoma Alismatis, 30～45 parts of Radix Salviae Miltiorrhizaes, 20～30 parts of Radix Polygoni Multiflori, 20～30 parts of Fructus Toosendans, 20～30 parts of Fructus Hippophaes, 20～30 parts of Radix Puerariaes, 20～30 parts of Herb Gynostemmae Pentaphylli, 10～20 parts of Semen Vaccariae, 10～20 parts of the Rhizoma Pinelliaes, 10～20 parts of Herba Lysimachiaes, 20～30 parts of Rhizoma Polygoni Cuspidati, 10～20 parts of Radix Paeoniae Rubra, 10～20 parts of Ganodermas, 10～20 parts, Radix Glycyrrhizae.
As preferred version, the above-described Traditional Chinese medicine compound composition with treatment fatty liver, it is made by the raw material of following parts by weight: 30 parts of Fructus Citris, 30 parts of Radix Et Rhizoma Rhei, 10 parts of Rhizoma Alismatis, 30 parts of Radix Salviae Miltiorrhizaes, 30 parts of Radix Polygoni Multiflori, 20 parts of Fructus Toosendans, 30 parts of Fructus Hippophaes, 30 parts of Radix Puerariaes, 30 parts of Herb Gynostemmae Pentaphylli, 10 parts of Semen Vaccariae, 10 parts of the Rhizoma Pinelliaes, 20 parts of Herba Lysimachiaes, 30 parts of Rhizoma Polygoni Cuspidati, 10 parts of Radix Paeoniae Rubra, 20 parts of Ganodermas, 20 parts, Radix Glycyrrhizae.
The Traditional Chinese medicine compound composition with treatment fatty liver of the present invention is prevented and treated the application in fatty liver medicine in preparation.
The present invention shows by lot of experiments, Traditional Chinese medicine compound composition provided by the invention can effectively reduce cholesterol, triglyceride and the low-density lipoprotein white level in hyperlipemia rat serum, improve hdl level, show that Traditional Chinese medicine compound composition provided by the invention has the function of good blood fat reducing.Experimental result shows in addition; Traditional Chinese medicine compound composition provided by the invention causes liver injury model animal serum ALT, AST activity and Liver MDA to ethanol; strengthen liver SOD active; show Chinese prescription compositions provided by the invention; there is obvious the liver protecting, improve the effect of liver function.
The Traditional Chinese medicine compound composition with treatment fatty liver of the present invention, in the lipotropic application of preparation, is made Traditional Chinese medicine compound composition and pharmaceutically acceptable carrier the medicine of soft capsule, hard capsule, tablet, drop pill, pill, micropill, powder, decoction, syrup, mixture, soft extract or extractum dosage form.
The Traditional Chinese medicine compound composition with treatment fatty liver provided by the invention is while making soft capsule, Traditional Chinese medicine compound composition extract or with mixing diluents evenly after, take gelatin, glycerol etc. is capsule casing material, uses encapsulating machine to be pressed into soft capsule.
When the Traditional Chinese medicine compound composition with treatment fatty liver provided by the invention is made hard capsule, Traditional Chinese medicine compound composition extract and lactose or corn starch mix homogeneously, or mix homogeneously with lactose or corn starch again after use cyclodextrin inclusion compound, through granulate, the encapsulated hard capsule of making then.
When the Traditional Chinese medicine compound composition with treatment fatty liver provided by the invention is made tablet, the extract of Traditional Chinese medicine compound composition and lactose or corn starch mix homogeneously, or mix homogeneously with lactose or corn starch again after use cyclodextrin inclusion compound, while needing, add magnesium stearate lubricant, then tabletting is made tablet.
Provided by the invention have treatment fatty liver the agent of Traditional Chinese medicine compound composition granulation time, the extract of Traditional Chinese medicine compound composition and lactose or corn starch mix homogeneously, or mix homogeneously with lactose or corn starch again after using cyclodextrin inclusion compound, granulate, dry, granulation agent.
When Traditional Chinese medicine compound composition provided by the invention is made other dosage form, can prepare by pharmacy conventional method.
The extracting method of the Traditional Chinese medicine compound composition with treatment fatty liver that invention is described is: gets each flavour of a drug of Traditional Chinese medicine compound composition, adds the ethanol of 6～12 times of amounts or water extraction 1 to 3 time, and each 1 to 3 hour, after extraction, concentrated, obtain extract.
Beneficial effect: the Traditional Chinese medicine compound composition with treatment fatty liver provided by the invention, according to the pathogeny of fatty liver, adopts the method for determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs; in conjunction with experiment screening prescription; in side, after each pharmaceutical science compatibility, can not only effectively reduce blood fat, reduce the effects such as cholesterol; play the effect of fat-reducing; can also blood circulation promoting and blood stasis dispelling, soothing the liver, promote hepatic cell growth, the liver protecting; improve the effect of liver function, obese type fatty liver is had to good prevention effect.And clinical test results shows, Traditional Chinese medicine compound composition provided by the invention, security performance is high, has no side effect.
The specific embodiment
Below in conjunction with specific embodiment, further illustrate the present invention, should understand these embodiment is only not used in and limits the scope of the invention for the present invention is described, after having read the present invention, those skilled in the art all fall within the application's claims limited range to the modification of the various equivalent form of values of the present invention.
Embodiment 1
A Traditional Chinese medicine compound composition with treatment fatty liver, it is made by the raw material of following parts by weight: 30 parts of Fructus Citris, 40 grams of Radix Et Rhizoma Rhei, 30 grams of Rhizoma Alismatis, 45 grams of Radix Salviae Miltiorrhizaes, 30 grams of Radix Polygoni Multiflori, 30 grams of Fructus Toosendans, 30 grams of Fructus Hippophaes, 30 grams of Radix Puerariaes, 30 grams of Herb Gynostemmae Pentaphylli, 20 grams of Semen Vaccariae, 20 grams of the Rhizoma Pinelliaes, 30 grams of Herba Lysimachiaes, 40 grams of Rhizoma Polygoni Cuspidati, 30 grams of Radix Paeoniae Rubra, 30 grams of Ganodermas, 20 grams, Radix Glycyrrhizae.
2 one kinds of Traditional Chinese medicine compound compositions with treatment fatty liver of embodiment, it is made by the raw material of following weight grams:
10 grams of Fructus Citris, 20 grams of Radix Et Rhizoma Rhei, 10 grams of Rhizoma Alismatis, 15 grams of Radix Salviae Miltiorrhizaes, 10 grams of Radix Polygoni Multiflori, 10 grams of Fructus Toosendans, 20 grams of Fructus Hippophaes, 10 grams of Radix Puerariaes, 10 grams of Herb Gynostemmae Pentaphylli, 10 grams of Semen Vaccariae, 10 grams of the Rhizoma Pinelliaes, 10 grams of Herba Lysimachiaes, 20 grams of Rhizoma Polygoni Cuspidati, 10 grams of Radix Paeoniae Rubra, 10 grams of Ganodermas, 10 grams, Radix Glycyrrhizae.
Get the straight alcohol that above-mentioned each flavour of a drug add 12 times of amounts, continuous circumfluence extraction 3 times, each 2 hours, merge extractive liquid,, the concentrated extract that obtains Traditional Chinese medicine compound composition.Then the extract of Traditional Chinese medicine compound composition being take to gelatin, glycerol etc. is capsule casing material, uses encapsulating machine to be pressed into soft capsule, every 0.5g.
Embodiment 3
A Traditional Chinese medicine compound composition with treatment fatty liver, it is made by the raw material of following weight grams: 30 grams of Fructus Citris, 30 grams of Radix Et Rhizoma Rhei, 20 grams of Rhizoma Alismatis, 45 grams of Radix Salviae Miltiorrhizaes, 30 grams of Radix Polygoni Multiflori, 20 grams of Fructus Toosendans, 20 grams of Fructus Hippophaes, 20～30 grams of Radix Puerariaes, 20 grams of Herb Gynostemmae Pentaphylli, 20 grams of Semen Vaccariae, 20 grams of the Rhizoma Pinelliaes, 120 grams of Herba Lysimachiaes, 20 grams of Rhizoma Polygoni Cuspidati, 20 grams of Radix Paeoniae Rubra, 20 grams of Ganodermas, 20 grams, Radix Glycyrrhizae.
Get the water that above-mentioned each flavour of a drug add 10 times of amounts, decoct and extract 2 times, each 3 hours, merge extractive liquid,, the concentrated extract that obtains Traditional Chinese medicine compound composition.Then after using cyclodextrin inclusion compound, mix homogeneously with lactose again, through granulate, the encapsulated hard capsule of making then.
4 one kinds of Traditional Chinese medicine compound compositions with treatment fatty liver of embodiment, it is made by the raw material of following weight grams:
30 grams of Fructus Citris, 30 grams of Radix Et Rhizoma Rhei, 10 grams of Rhizoma Alismatis, 30 grams of Radix Salviae Miltiorrhizaes, 30 grams of Radix Polygoni Multiflori, 20 grams of Fructus Toosendans, 30 grams of Fructus Hippophaes, 30 grams of Radix Puerariaes, 30 grams of Herb Gynostemmae Pentaphylli, 10 grams of Semen Vaccariae, 10 grams of the Rhizoma Pinelliaes, 20 grams of Herba Lysimachiaes, 30 grams of Rhizoma Polygoni Cuspidati, 10 grams of Radix Paeoniae Rubra, 20 grams of Ganodermas, 20 grams, Radix Glycyrrhizae.
Get the ethanol that above-mentioned each flavour of a drug add 10 times of amounts, reflux, extract, 3 times, each 3 hours, merge extractive liquid,, the concentrated extract that obtains Traditional Chinese medicine compound composition.Then get the extract of Traditional Chinese medicine compound composition and starch mixing diluents evenly after, take gelatin, glycerol is capsule casing material, uses encapsulating machine to be pressed into soft capsule.
Embodiment 5
Get Traditional Chinese medicine compound composition and lactose mix homogeneously that the embodiment of the present invention 1 prepares, add magnesium stearate lubricant, then tabletting is made tablet.
Embodiment 6 lipid-lowering test researchs
One, experiment material and medicine
1. medicine and reagent
T-CHOL (TC) is measured test kit, and triglyceride (TG) is measured test kit, and HDL-C (HDL-C) is measured test kit, all purchased from Nanjing, builds up Bioengineering Research Institute.High lipid food formula: cholesterol 4%, Adeps Sus domestica 10%, methylthiouracil 0.2%, cholate 0.5%%, normal feedstuff 85%.
2. experimental apparatus
Enzyme linked immunological instrument (U.S. Bio-Tek company); UV-2000 type ultraviolet spectrophotometer (Beijing Lai Baitaike Instrument Ltd.); BT125 type electronic balance (Sai Duolisi scientific instrument company limited); KQ-250E type ultrasonic cleaner (Kunshan He Chuan ultrasonic instrument company limited).
3. laboratory animal
Clean level male ICR mouse, body weight 18～22g, is provided by Zhejiang Province's Experimental Animal Center, quality certification SCXK (Zhejiang) 2008-0033.
Two, experimental technique
1. the foundation of high blood lipid model
Healthy mice adaptability is fed after 3d, and random packet, is respectively blank group, hyperlipidemia model group and the basic, normal, high concentration dose group of tested Traditional Chinese medicine compound composition, and 10 every group, to weigh and keep a record, each organizes the different not statistically significant of the mesosome method of double differences.Experiment mice is except blank group, and all the other respectively organize feeding high lipid food with the formation of induction hyperlipidemia.After 20d, from blank group and high fat group, respectively extract 4 mices at random, pluck eyeball and get hematometry T-CHOL (TC), triglyceride (TG) and HDL-C (HDL-C) level, to determine the foundation of hyperlipidemia model.
2. hyperlipidemia experimental technique
The common Mus grain of blank group feeding, the mice of built vertical hyperlipidemia continues feeding high lipid food, and animal freely ingests and drinks water.The high, medium and low dosage group of Traditional Chinese medicine compound composition every day that the embodiment of the present invention 1 and embodiment 4 are prepared is respectively with 18g/kg, 6g/kg, the corresponding tested material of 2g/kg gavage, blank group and hyperlipidemia model group gavage equivalent distilled water, continuous gavage 20d, rear fasting 24h, after weighing, pluck eyeball and get blood and liver, according to reagent packed meal description, measure the concentration of TC, TG and HDL-C indices.
3. statistical procedures
All experimental datas all adopt SPSS11.5 statistical processing software to carry out statistical procedures, result with
represent, group difference adopts t check, and P<0.05 is that difference has statistical significance.
Three, experimental result
Blood fat reducing result of the test
Mice is given respectively after the Traditional Chinese medicine compound composition preparing with embodiment 1 and embodiment 4, measures the content of TC, TG and HLD-C in its serum.Result is as shown in table 1, high lipid food group and the comparison of blank group, nursing through 40d, pathological model group mice serum TC and TG content are all apparently higher than blank group (P<0.01), HLD-C content is all starkly lower than blank group (P<0.01), illustrates that the hyperlipidemia animal model in this experiment is successful.Compare with high fat pathological model group, give embodiment 1 and the embodiment high, medium and low dosage group of 4 gained Traditional Chinese medicine compound composition and positive controls and all reduced mice serum TC and TG content, HLD-C content has raise.Wherein combine object height, middle dosage group is compared with hyperlipidemia model group, TC, TG and HLD-C level difference have statistical significance (P<0.05), show that Traditional Chinese medicine compound composition provided by the present invention is to having good effect for reducing blood fat.
Table 1 Traditional Chinese medicine compound composition on the impact of high blood lipid model mice TC, TG and HDL-C content (
n=10)
Note:
##p<0.01, represents and the comparison of blank group;
*: P<0.05,
*p<0.01, represents and model group comparison.
Above experimental result shows, Traditional Chinese medicine compound composition provided by the invention has the effect of good blood fat reducing, improves the dyslipidemia of Patients with Fatty Liver, fundamentally the fatty effect of performance treatment.
The liver-protective experimentation of embodiment 7
One, experiment material and medicine
1. medicine and reagent
AST, ALT, MDA, SOD test kit and Coomassie brilliant blue protein reagent box are all purchased from Nanjing and build up Bioengineering Research Institute.
2. laboratory animal
Clean level male ICR mouse, body weight 18～22g, is provided by Zhejiang Province's Experimental Animal Center, quality certification SCXK (Zhejiang) 2008-0033.
3. experimental apparatus
Enzyme linked immunological instrument (U.S. Bio-Tek company); UV-2000 type ultraviolet spectrophotometer (Beijing Lai Baitaike Instrument Ltd.); BT125 type electronic balance (Sai Duolisi scientific instrument company limited); KQ-250E type ultrasonic cleaner (Kunshan He Chuan ultrasonic instrument company limited);
4. tested medicine and processing method
Get respectively the Traditional Chinese medicine compound composition that embodiment 1 and embodiment 3 prepare.
Two, experimental technique
Get mice, adaptability was fed after 1 week, by body weight random packet, every group 10, be respectively Normal group, ethanol causes liver injury model group, the Traditional Chinese medicine compound composition low dose group (3.0mL/kg/d) that embodiment 1 and embodiment 3 prepare respectively, middle dosage group (6mL/kg/d) and high dose group (12mL/kg/d).Except Normal group (with isopyknic distilled water gavage), all the other each groups all give 55 degree Red Star strong, colourless liquor distilled from sorghum by 7mL/kg/ gavage, and 2 times/d, midfeather 6h, continuously 15d.From modeling the 1st day, every day, gastric infusion was 1 time.Normal group and model control group gavage isopyknic distilled water, and all the other are respectively organized gavage respectively and give corresponding Traditional Chinese medicine compound composition.After last 1 gavage 6h, all mices adopt the blood sampling of eye socket rear vein beard, separation of serum, the activity of mensuration serum alt and AST.After getting blood, put to death mice, get immediately part liver, with normal saline, be prepared into 10% liver homogenate, according to test kit explanation, measure MDA content and SOD vigor.
4. statistical procedures
All experimental datas all adopt SPSS11.5 statistical processing software to carry out statistical procedures, result with
represent, between group, relatively adopt variance analysis.
Three, experimental result
Ethanol causes liver injury model group and normal group comparison, and mice serum ALT, AST and hepatic tissue MDA level obviously raise (P<0.01), active obviously reduce (P<0.01) of SOD; Each dosage group of the Traditional Chinese medicine compound composition that embodiment 1 and embodiment 3 prepare and model group make hepatic injury mice serum ALT, AST reduce (P<0.05) more to some extent; Each dosage group of Traditional Chinese medicine compound composition and model group make hepatic injury murine liver tissue MDA level reduce (P<0.05) more to some extent, SOD level rising (P<0.05).Specific experiment the results are shown in Table 2.
Table 2 Traditional Chinese medicine compound composition causes the impact of acute hepatic injury mice Serum ALT, AST and liver SOD, MDA on ethanol
(mean±SD，n＝10)
Note: with model group comparison,
##p<0.01,
#p<0.05.
Experimental result by table 2 shows; Traditional Chinese medicine compound composition provided by the invention can significantly reduce liver injury model mice serum ALT due to ethanol, AST activity and Liver MDA; strengthen liver SOD active; show that middle compound provided by the invention has good the liver protecting, improves the effect of liver function.
Embodiment 8 clinical and experimental studies
Choose patient's 180 examples that are diagnosed as fatty liver, take the Traditional Chinese medicine compound composition that the embodiment of the present invention 4 prepares, and during taking, cut out other medicine, take after 2 months, biochemical indicator detects and B ultrasonic detects, and obviously playing efficiency is 85%, and total effective rate is 95%.And in experimentation, find no untoward reaction, take safety.Be expected to exploitation and become new lipotropic medicine.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (5)
1. one kind has the Traditional Chinese medicine compound composition for the treatment of fatty liver, it is characterized in that, it is made by the raw material of following parts by weight: 10 ~ 30 parts of Fructus Citris, 20 ~ 40 parts of Radix Et Rhizoma Rhei, 10 ~ 30 parts of Rhizoma Alismatis, 15 ~ 45 parts of Radix Salviae Miltiorrhizaes, 10 ~ 30 parts of Radix Polygoni Multiflori, 10 ~ 30 parts of Fructus Toosendans, 20 ~ 30 parts of Fructus Hippophaes, 10 ~ 30 parts of Radix Puerariaes, 10 ~ 30 parts of Herb Gynostemmae Pentaphylli, 10 ~ 20 parts of Semen Vaccariae, 10 ~ 20 parts of the Rhizoma Pinelliaes, 10 ~ 30 parts of Herba Lysimachiaes, 20 ~ 40 parts of Rhizoma Polygoni Cuspidati, 10 ~ 30 parts of Radix Paeoniae Rubra, 10 ~ 30 parts of Ganodermas, 10 ~ 20 parts, Radix Glycyrrhizae.
According to claim 1 have treatment fatty liver Traditional Chinese medicine compound composition, it is characterized in that, it is made by the raw material of following parts by weight: 20 ~ 30 parts of Fructus Citris, 30 ~ 40 parts of Radix Et Rhizoma Rhei, 10 ~ 20 parts of Rhizoma Alismatis, 30 ~ 45 parts of Radix Salviae Miltiorrhizaes, 20 ~ 30 parts of Radix Polygoni Multiflori, 20 ~ 30 parts of Fructus Toosendans, 20 ~ 30 parts of Fructus Hippophaes, 20 ~ 30 parts of Radix Puerariaes, 20 ~ 30 parts of Herb Gynostemmae Pentaphylli, 10 ~ 20 parts of Semen Vaccariae, 10 ~ 20 parts of the Rhizoma Pinelliaes, 10 ~ 20 parts of Herba Lysimachiaes, 20 ~ 30 parts of Rhizoma Polygoni Cuspidati, 10 ~ 20 parts of Radix Paeoniae Rubra, 10 ~ 20 parts of Ganodermas, 10 ~ 20 parts, Radix Glycyrrhizae.
According to claim 2 have treatment fatty liver Traditional Chinese medicine compound composition, it is characterized in that, it is made by the raw material of following parts by weight: 30 parts of Fructus Citris, 30 parts of Radix Et Rhizoma Rhei, 10 parts of Rhizoma Alismatis, 30 parts of Radix Salviae Miltiorrhizaes, 30 parts of Radix Polygoni Multiflori, 20 parts of Fructus Toosendans, 30 parts of Fructus Hippophaes, 30 parts of Radix Puerariaes, 30 parts of Herb Gynostemmae Pentaphylli, 10 parts of Semen Vaccariae, 10 parts of the Rhizoma Pinelliaes, 20 parts of Herba Lysimachiaes, 30 parts of Rhizoma Polygoni Cuspidati, 10 parts of Radix Paeoniae Rubra, 20 parts of Ganodermas, 20 parts, Radix Glycyrrhizae.
4. the application of the Traditional Chinese medicine compound composition with treatment fatty liver described in claims 1 to 3 any one in preparation control fatty liver medicine.
5. the Traditional Chinese medicine compound composition with treatment fatty liver according to claim 4 prevents the application in hyperlipidemia disease in preparation, it is characterized in that, the extract of Traditional Chinese medicine compound composition and pharmaceutically acceptable carrier are made to the medicine of soft capsule, hard capsule, tablet, drop pill, pill, micropill, powder, decoction, syrup, mixture, soft extract or extractum dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410206652.0A CN103948759B (en) | 2014-05-15 | 2014-05-15 | A kind of Traditional Chinese medicine compound composition and its application with treatment fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410206652.0A CN103948759B (en) | 2014-05-15 | 2014-05-15 | A kind of Traditional Chinese medicine compound composition and its application with treatment fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103948759A true CN103948759A (en) | 2014-07-30 |
| CN103948759B CN103948759B (en) | 2017-03-15 |
Family
ID=51326200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410206652.0A Expired - Fee Related CN103948759B (en) | 2014-05-15 | 2014-05-15 | A kind of Traditional Chinese medicine compound composition and its application with treatment fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103948759B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115969903A (en) * | 2022-12-16 | 2023-04-18 | 上海中医药大学附属龙华医院 | A Chinese medicinal composition, its preparation method, and its application in preparing medicine for preventing and treating fatty liver |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391079A (en) * | 2008-11-06 | 2009-03-25 | 徐朝阳 | Traditional Chinese medicine for treating fatty liver |
| CN103736036A (en) * | 2014-01-28 | 2014-04-23 | 张怀胜 | Drug for treating nonalcoholic fatty liver disease and preparation method thereof |
-
2014
- 2014-05-15 CN CN201410206652.0A patent/CN103948759B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391079A (en) * | 2008-11-06 | 2009-03-25 | 徐朝阳 | Traditional Chinese medicine for treating fatty liver |
| CN103736036A (en) * | 2014-01-28 | 2014-04-23 | 张怀胜 | Drug for treating nonalcoholic fatty liver disease and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 马会芳等: "脂肪肝中医药治疗研究进展", 《中国民族民间医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115969903A (en) * | 2022-12-16 | 2023-04-18 | 上海中医药大学附属龙华医院 | A Chinese medicinal composition, its preparation method, and its application in preparing medicine for preventing and treating fatty liver |
| CN115969903B (en) * | 2022-12-16 | 2024-02-09 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition, preparation method thereof and application of traditional Chinese medicine composition in preparation of medicines with fatty liver prevention and treatment effects |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103948759B (en) | 2017-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11160842B2 (en) | Drug or health care product preventing or treating liver and kidney damage-related diseases and use thereof | |
| CN103182009B (en) | Hypolipidemic traditional Chinese medicine composition and preparation method and application thereof | |
| CN103372051B (en) | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition | |
| CN101007080A (en) | Chinese medicinal preparation for lowering blood fat and benefiting liver | |
| CN103800352B (en) | Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN106266949A (en) | A kind of compound Chinese medicinal preparation and its preparation method and application | |
| CN103610051A (en) | Food, healthcare food or medicine composition with lipid-lowering effect as well as preparation methods and applications thereof | |
| CN101264169A (en) | Qingchun jiangan capsule and manufacturing technique | |
| CN103948759A (en) | Traditional Chinese medicine compound composition and application for treating fatty liver | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| CN115006494A (en) | Inula flower composite anti-alcohol composition with pulse-displaying function, anti-alcohol and liver-protecting preparation and application thereof | |
| CN103372040B (en) | Monas cuspurpureus Went Rhizoma Chuanxiong drug regimen of a kind of adjusting blood lipid and preparation method thereof | |
| CN108404088B (en) | Traditional Chinese medicine for treating type II diabetes and preparation method thereof | |
| US11957726B2 (en) | Pharmaceutical composition for controlling blood sugar | |
| CN107997170B (en) | Composition with blood fat reducing function and preparation method thereof | |
| CN107184831B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN103372114B (en) | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition | |
| CN113694105B (en) | Composition with blood fat reducing function and application thereof | |
| CN102836315A (en) | Chinese medicinal composition for preventing and conditioning prognosis tumors and preparation method thereof | |
| CN103239606A (en) | Ginseng composition and application thereof in aspect of adjunctively improving memory | |
| CN102631486B (en) | Health care composition | |
| WO2023025228A1 (en) | Traditional chinese medicine composition, and preparation method therefor and use thereof | |
| CN100340267C (en) | Chinese medicinal preparation for treating fattly liver | |
| CN101549109B (en) | Medicament for treating cerebral atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170315 Termination date: 20170515 |